September 30, 2020 by Chain Drug Review
drug pricing, Innopiphany
Leading Headlines, Pharmacy
LOS ANGELES — Going into the 2020 election, drug pricing remains a key topic of discussion, and has been so for a long time as almost half of all Americans take at least one prescription medication daily. While lawmakers continue to promise reform, nearly all regulatory progress stalls before it can take effect. The key
July 5, 2018 by Chain Drug Review
drug pricing, Mark Merritt, PCMA, Pharmaceutical Care Management Association
Leading Headlines, Pharmacy
WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and chief executive officer Mark Merritt released the following statement on reports of yet another round of massive price hikes by drug manufacturers. “News of recent price increases by drugmakers further confirms that the easiest way to lower costs would be for drug companies to lower their prices.” This
May 11, 2018 by Chain Drug Review
Alex Azar, American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, drug pricing, NACDS
Leading Headlines, Pharmacy
ARLINGTON, Va. — NACDS today sent the following memo to chain members: We are writing to update you on President Trump’s announcement today regarding prescription drug pricing policies, and anticipated future events related to it. In short, we anticipate learning more details in the coming days, and NACDS will analyze the Administration’s proposals and provide
November 6, 2017 by Chain Drug Review
drug pricing, Hercules Pharmaceuticals, NASP, National Association of Specialty Pharmacy, Onco360, Paul Jardina, Sheila Arquette, specialty pharmacy, Timothy Ward, Tom Suozzi
2017, Issue 11-06-2017, Issues, News
GREAT NECK, N.Y. — Rep. Tom Suozzi (D., N.Y.) got an education on drug cost dynamics during a tour of oncology pharmacy Onco360 here with members of the National Association of Specialty Pharmacy (NASP). Vice chairman of the Problem Solvers Caucus in the House of Representatives, Suozzi said he made the visit to learn more
October 20, 2017 by CDR Blog and Chain Drug Review
drug pricing, NASP, National Association of Specialty Pharmacy, Onco360, pharmacy industry, prescription drug costs, Tom Suozzi
CDR Blog
No one claims to hold “the solution” to soaring costs for prescription drugs and how Americans and payers — including government — can afford to pay for them. But strides toward unraveling the tangle of problems behind this issue won’t be made without determined attempts at substantive discussion between the public and private sectors, according
January 12, 2017 by CDR Blog and Chain Drug Review
B. Douglas Hoey, Donald Trump, drug industry, drug pricing, National Community Pharmacists Association, NCPA, PBMs, pharmaceutical industry, pharmacy benefit managers, prescription drug prices
CDR Blog
Donald Trump briefly touched on the pharmaceutical industry in his first major press conference since being elected president. In the news conference yesterday at Trump Tower in Manhattan, Trump talked about drug companies relocating overseas and referred to the rising cost of pharmaceuticals. “We’ve got to get our drug industry back,” Trump said after discussing
January 3, 2017 by David Farber and Chain Drug Review
Affordable Care Act, David Farber, Donald Trump, drug pricing, King & Spalding, Medicaid, Medicare, Obamacare, Trump administration
2017, Issue 01-02-2017, Issues, Leading Headlines, Opinion
The January 20, 2017, inauguration of President Trump as the nation’s 45th president is certain to bring with it changes in the health care environment, which may impact pharmacy in a variety of ways. As important as the new administration, however, is the fact that a “unified” government will take over in Washington, with Republicans
September 26, 2016 by Greg Jacobson and Chain Drug Review
2016 presidential election, Affordable Care Act, Donald Trump, drug pricing, generic drugs, health care, Hillary Clinton, prescription drug costs
2016, Business, Issue 09-26-2016, Issues, Leading Headlines, News, Retail News
NEW YORK — With the 2016 presidential election drawing near, health care has emerged as a policy area in which the two major candidates’ differences are strikingly clear. A useful starting point might be their respective approaches to prescription drug pricing. The Republican candidate, Donald Trump, created a sensation in January when he advocated allowing